Relationship between the frequency of influenza vaccination and cell-mediated immunity

Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-med...

Full description

Saved in:
Bibliographic Details
Published inJournal of immunological methods Vol. 458; pp. 58 - 62
Main Authors Otani, Naruhito, Shima, Masayuki, Ueda, Takashi, Ichiki, Kaoru, Nakajima, Kazuhiko, Takesue, Yoshio, Honjo, Kenta, Yoshida, Natsuko, Kawata, Sayo, Okuno, Toshiomi
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.07.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure. •Cell-mediated immunity was assessed after one and two vaccine doses.•A second vaccine dose enhanced CMI in subjects with primary vaccine failure.•In subjects with CMI after one dose, a second dose did not act as a booster.•There was significant correlation between the HAI antibody titer and NT.•There was no significant correlation between CMI and the HAI antibody titer and NT.
AbstractList Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure.
Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015-2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure.Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015-2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure.
Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been established, limiting the ability to optimize vaccination strategies within a particular season. In this study, we evaluated changes in cell-mediated immunity (CMI) with respect to the number of influenza vaccine doses. In particular, the influenza vaccine was administered to 21 adults during the 2015–2016 season. IFN-γ production induced by the influenza vaccine antigens [A (H1N1), A (H3N2), B (Yamagata lineage), and B (Victoria lineage)] increased after the first dose of vaccination in 11, 10, 10, and 11 subjects, respectively. In 5 of 10 (H1N1), 4 of 10 (H3N2), 3 of 9 (Yamagata lineage), and 3 of 8 (Victoria lineage) subjects who did not exhibit an increase in IFN-γ production after the first dose, CMI was enhanced after the second dose. The production of IFN-γ increased after the first or second dose of the vaccine in 16, 14, 13, and 14 of the 21 subjects, respectively. The results of this study showed that two doses of the influenza vaccine effectively enhance CMI in subjects with primary vaccine failure. •Cell-mediated immunity was assessed after one and two vaccine doses.•A second vaccine dose enhanced CMI in subjects with primary vaccine failure.•In subjects with CMI after one dose, a second dose did not act as a booster.•There was significant correlation between the HAI antibody titer and NT.•There was no significant correlation between CMI and the HAI antibody titer and NT.
Author Otani, Naruhito
Yoshida, Natsuko
Honjo, Kenta
Okuno, Toshiomi
Ichiki, Kaoru
Nakajima, Kazuhiko
Takesue, Yoshio
Ueda, Takashi
Kawata, Sayo
Shima, Masayuki
Author_xml – sequence: 1
  givenname: Naruhito
  surname: Otani
  fullname: Otani, Naruhito
  email: naruhito@fa2.so-net.ne.jp
  organization: Department of Public Health, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 2
  givenname: Masayuki
  orcidid: 0000-0002-8783-7879
  surname: Shima
  fullname: Shima, Masayuki
  organization: Department of Public Health, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 3
  givenname: Takashi
  surname: Ueda
  fullname: Ueda, Takashi
  organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 4
  givenname: Kaoru
  surname: Ichiki
  fullname: Ichiki, Kaoru
  organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 5
  givenname: Kazuhiko
  surname: Nakajima
  fullname: Nakajima, Kazuhiko
  organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 6
  givenname: Yoshio
  surname: Takesue
  fullname: Takesue, Yoshio
  organization: Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
– sequence: 7
  givenname: Kenta
  surname: Honjo
  fullname: Honjo, Kenta
  organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan
– sequence: 8
  givenname: Natsuko
  surname: Yoshida
  fullname: Yoshida, Natsuko
  organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan
– sequence: 9
  givenname: Sayo
  surname: Kawata
  fullname: Kawata, Sayo
  organization: Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061, Japan
– sequence: 10
  givenname: Toshiomi
  surname: Okuno
  fullname: Okuno, Toshiomi
  organization: Department of Microbiology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29684427$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1r3DAQhkVJaTZpf0Avxcde7I5kfdj0VEK_IFAoba9ClkZEiy1vJW3C9tdXm00uPaQnMfA8w-h9L8hZXCMS8ppCR4HKd9tuG5aOAR064B3A8Ixs6KBYq0YQZ2QDwFhLlRjPyUXOWwCgIOEFOWejHDhnakN-fcfZlLDGfBN2zYTlDjE25QYbn_D3HqM9NKtvQvRzHf6Y5tZYG-K90pjoGovz3C7oginomrAs-xjK4SV57s2c8dXDe0l-fvr44-pLe_3t89erD9et5YKVVsh-mhgqKxkbECekzo9CUMVHJ5CPXvUSRymdn3rlvKMw9jjYHpXkAML1l-Ttae8urfXaXPQS8vEkE3HdZ82o6GXPKIX_o9BXqm7lFX3zgO6n-jW9S2Ex6aAfY6uAOgE2rTkn9NqGcp9JSSbMmoI-FqS3uhakjwVp4LoWVE36j_m4_Cnn_cnBmuRtwKSzDbWZGnpCW7RbwxP2XxCrqG4
CitedBy_id crossref_primary_10_3390_vaccines12060584
crossref_primary_10_3390_v13061137
crossref_primary_10_1111_1348_0421_12687
Cites_doi 10.1128/CVI.00397-07
10.1002/jmv.22273
10.1016/j.vaccine.2009.01.136
10.15585/mmwr.mm6430a3
10.1016/j.jim.2009.09.010
10.2169/internalmedicine.56.7533
10.1016/j.jim.2014.06.006
10.1056/NEJMcp1512870
10.1186/s12879-016-1978-0
10.1371/journal.ppat.0030151
10.1016/j.cellimm.2016.09.005
10.2807/1560-7917.ES.2016.21.11.30168
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
NPM
7X8
7S9
L.6
DOI 10.1016/j.jim.2018.04.008
DatabaseName CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1872-7905
EndPage 62
ExternalDocumentID 29684427
10_1016_j_jim_2018_04_008
S0022175918300309
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29K
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXUO
ABEFU
ABFNM
ABFRF
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFFNX
AFKWA
AFTJW
AFXIZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AI.
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
CJTIS
CNWQP
CS3
D-I
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMG
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LUGTX
M41
MO0
N9A
O-L
O9-
OAUVE
OHT
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSI
SSU
SSZ
T5K
UAP
VH1
WUQ
X7M
XFK
XPP
Y6R
ZGI
ZMT
~G-
AAHBH
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c452t-563bb2e7c6228eebe1df9551749d5e49f736e966dfb37dfd1093e8c3e764005d3
IEDL.DBID .~1
ISSN 0022-1759
1872-7905
IngestDate Thu Jul 10 23:13:29 EDT 2025
Fri Jul 11 11:44:56 EDT 2025
Wed Feb 19 02:35:51 EST 2025
Thu Apr 24 23:05:42 EDT 2025
Tue Jul 01 03:53:58 EDT 2025
Fri Feb 23 02:31:07 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Cell-mediated immunity
NT
IR
one dose
Hemagglutination inhibition
Neutralizing antibody
GMT
two doses
HAI
IFN-γ
IIV
Influenza vaccine
CMI
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c452t-563bb2e7c6228eebe1df9551749d5e49f736e966dfb37dfd1093e8c3e764005d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8783-7879
PMID 29684427
PQID 2031030054
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_2153632110
proquest_miscellaneous_2031030054
pubmed_primary_29684427
crossref_citationtrail_10_1016_j_jim_2018_04_008
crossref_primary_10_1016_j_jim_2018_04_008
elsevier_sciencedirect_doi_10_1016_j_jim_2018_04_008
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-07-01
PublicationDateYYYYMMDD 2018-07-01
PublicationDate_xml – month: 07
  year: 2018
  text: 2018-07-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Journal of immunological methods
PublicationTitleAlternate J Immunol Methods
PublicationYear 2018
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (bb0025) 1997
Otani, Shima, Nakajima, Takesue, Okuno (bb0070) 2014; 411
Forrest, Pride, Dunning, Capeding, Chotpitayasunondh, Tam, Rappaport, Eldridge, Gruber (bb0030) 2008; 15
National Institute of Infectious Diseases (NIID) (bb0060) 2017
Treanor (bb0085) 2016; 375
Ainai, Tamura, Suzuki, Ito, Asanuma, Tanimoto, Gomi, Manabe, Ishikawa, Okuno, Odagiri (bb0005) 2012; 84
INFLUENZA VACCINE “BIKEN” package insert, 26th ed. (Japanese).
McElhaney, Ewen, Zhou, Kane, Xie, Hager, Barry, Kleppinger, Wang, Bleackley (bb0055) 2009; 27
Lowen, Mubareka, Steel, Palese (bb0050) 2007; 3
Tanabe, Nakamura, Arai, Yamasaki, Hirano, Kobayashi, Taguchi, Kaneko, Ito (bb0080) 2017; 56
Centers for Disease Control and Prevention (CDC) (bb0015) 2017
Otani, Shima, Ueda, Ichiki, Nakajima, Takesue, Okuno (bb0075) 2016; 310
Centers for Disease Control and Prevention (CDC) (bb0010) 2015
Grohskopf, Sokolow, Olson, Bresee, Broder, Karron (bb0035) 2015; 64
Iha, Kinjo, Parrott, Higa, Mori, Fujita (bb0040) 2016; 16
Chambers, Skowronski, Sabaiduc, Winter, Dickinson, De Serres, Gubbay, Drews, Martineau, Eshaghi, Krajden (bb0020) 2016; 21
Otani, Baba, Okuno (bb0065) 2009; 351
Otani (10.1016/j.jim.2018.04.008_bb0075) 2016; 310
Tanabe (10.1016/j.jim.2018.04.008_bb0080) 2017; 56
Treanor (10.1016/j.jim.2018.04.008_bb0085) 2016; 375
Iha (10.1016/j.jim.2018.04.008_bb0040) 2016; 16
Otani (10.1016/j.jim.2018.04.008_bb0065) 2009; 351
Ainai (10.1016/j.jim.2018.04.008_bb0005) 2012; 84
10.1016/j.jim.2018.04.008_bb0045
Chambers (10.1016/j.jim.2018.04.008_bb0020) 2016; 21
McElhaney (10.1016/j.jim.2018.04.008_bb0055) 2009; 27
European Agency for the Evaluation of Medicinal Products (EMEA) (10.1016/j.jim.2018.04.008_bb0025) 1997
Grohskopf (10.1016/j.jim.2018.04.008_bb0035) 2015; 64
Lowen (10.1016/j.jim.2018.04.008_bb0050) 2007; 3
National Institute of Infectious Diseases (NIID) (10.1016/j.jim.2018.04.008_bb0060) 2017
Centers for Disease Control and Prevention (CDC) (10.1016/j.jim.2018.04.008_bb0010) 2015
Otani (10.1016/j.jim.2018.04.008_bb0070) 2014; 411
Centers for Disease Control and Prevention (CDC) (10.1016/j.jim.2018.04.008_bb0015) 2017
Forrest (10.1016/j.jim.2018.04.008_bb0030) 2008; 15
References_xml – year: 1997
  ident: bb0025
  article-title: Note for guidance on harmonization of requirements for influenza vaccines
– volume: 16
  start-page: 650
  year: 2016
  ident: bb0040
  article-title: Comparative epidemiology of influenza A and B viral infection in a subtropical region: a 7-year surveillance in Okinawa, Japan
  publication-title: BMC Infect. Dis.
– volume: 64
  start-page: 818
  year: 2015
  end-page: 825
  ident: bb0035
  article-title: Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season
  publication-title: MMWR Morb. Mortal. Wkly Rep.
– volume: 21
  year: 2016
  ident: bb0020
  article-title: Interim estimates of 2015/16 vaccine effectiveness against influenza A (H1N1) pdm09, Canada, February 2016
  publication-title: Euro. Surveill.
– volume: 310
  start-page: 165
  year: 2016
  end-page: 169
  ident: bb0075
  article-title: Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity
  publication-title: Cell. Immunol.
– volume: 351
  start-page: 71
  year: 2009
  end-page: 74
  ident: bb0065
  article-title: Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity
  publication-title: J. Immunol. Methods
– volume: 3
  start-page: 1470
  year: 2007
  end-page: 1476
  ident: bb0050
  article-title: Influenza virus transmission is dependent on relative humidity and temperature
  publication-title: PLoS Pathog.
– year: 2017
  ident: bb0060
  article-title: Weekly reports of influenza virus isolation/detection, week 20/2016-week 3/2017
– volume: 56
  start-page: 773
  year: 2017
  end-page: 779
  ident: bb0080
  article-title: The direct comparison of two interferon-gamma release assays in the tuberculosis screening of Japanese healthcare workers
  publication-title: Intern. Med.
– volume: 27
  start-page: 2418
  year: 2009
  end-page: 2425
  ident: bb0055
  article-title: Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults
  publication-title: Vaccine
– volume: 15
  start-page: 1042
  year: 2008
  end-page: 1053
  ident: bb0030
  article-title: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children
  publication-title: Clin. Vaccine Immunol.
– reference: INFLUENZA VACCINE “BIKEN” package insert, 26th ed. (Japanese).
– year: 2017
  ident: bb0015
  article-title: Summary of the 2015–2016 influenza season
– volume: 375
  start-page: 1261
  year: 2016
  end-page: 1268
  ident: bb0085
  article-title: Clinical practice. Influenza vaccination
  publication-title: N. Engl. J. Med.
– volume: 84
  start-page: 336
  year: 2012
  end-page: 344
  ident: bb0005
  article-title: Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine
  publication-title: J. Med. Virol.
– start-page: 187
  year: 2015
  end-page: 207
  ident: bb0010
  article-title: Influenza
  publication-title: Epidemiology and Prevention of Vaccine-Preventable Diseases
– volume: 411
  start-page: 50
  year: 2014
  end-page: 54
  ident: bb0070
  article-title: Development of a simplified and convenient assay for cell-mediated immunity to the mumps virus
  publication-title: J. Immunol. Methods
– start-page: 187
  year: 2015
  ident: 10.1016/j.jim.2018.04.008_bb0010
  article-title: Influenza
– volume: 15
  start-page: 1042
  year: 2008
  ident: 10.1016/j.jim.2018.04.008_bb0030
  article-title: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00397-07
– volume: 84
  start-page: 336
  year: 2012
  ident: 10.1016/j.jim.2018.04.008_bb0005
  article-title: Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.22273
– volume: 27
  start-page: 2418
  year: 2009
  ident: 10.1016/j.jim.2018.04.008_bb0055
  article-title: Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.01.136
– volume: 64
  start-page: 818
  year: 2015
  ident: 10.1016/j.jim.2018.04.008_bb0035
  article-title: Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season
  publication-title: MMWR Morb. Mortal. Wkly Rep.
  doi: 10.15585/mmwr.mm6430a3
– volume: 351
  start-page: 71
  year: 2009
  ident: 10.1016/j.jim.2018.04.008_bb0065
  article-title: Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2009.09.010
– volume: 56
  start-page: 773
  year: 2017
  ident: 10.1016/j.jim.2018.04.008_bb0080
  article-title: The direct comparison of two interferon-gamma release assays in the tuberculosis screening of Japanese healthcare workers
  publication-title: Intern. Med.
  doi: 10.2169/internalmedicine.56.7533
– ident: 10.1016/j.jim.2018.04.008_bb0045
– year: 2017
  ident: 10.1016/j.jim.2018.04.008_bb0060
– volume: 411
  start-page: 50
  year: 2014
  ident: 10.1016/j.jim.2018.04.008_bb0070
  article-title: Development of a simplified and convenient assay for cell-mediated immunity to the mumps virus
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2014.06.006
– volume: 375
  start-page: 1261
  year: 2016
  ident: 10.1016/j.jim.2018.04.008_bb0085
  article-title: Clinical practice. Influenza vaccination
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMcp1512870
– year: 2017
  ident: 10.1016/j.jim.2018.04.008_bb0015
– year: 1997
  ident: 10.1016/j.jim.2018.04.008_bb0025
– volume: 16
  start-page: 650
  year: 2016
  ident: 10.1016/j.jim.2018.04.008_bb0040
  article-title: Comparative epidemiology of influenza A and B viral infection in a subtropical region: a 7-year surveillance in Okinawa, Japan
  publication-title: BMC Infect. Dis.
  doi: 10.1186/s12879-016-1978-0
– volume: 3
  start-page: 1470
  year: 2007
  ident: 10.1016/j.jim.2018.04.008_bb0050
  article-title: Influenza virus transmission is dependent on relative humidity and temperature
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.0030151
– volume: 310
  start-page: 165
  year: 2016
  ident: 10.1016/j.jim.2018.04.008_bb0075
  article-title: Evaluation of influenza vaccine-immunogenicity in cell-mediated immunity
  publication-title: Cell. Immunol.
  doi: 10.1016/j.cellimm.2016.09.005
– volume: 21
  year: 2016
  ident: 10.1016/j.jim.2018.04.008_bb0020
  article-title: Interim estimates of 2015/16 vaccine effectiveness against influenza A (H1N1) pdm09, Canada, February 2016
  publication-title: Euro. Surveill.
  doi: 10.2807/1560-7917.ES.2016.21.11.30168
SSID ssj0001060
Score 2.2511194
Snippet Despite established guidelines for population-level assessments of immunity after vaccination, standard methods for individual-level analyses have not been...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 58
SubjectTerms adults
antigens
Cell-mediated immunity
guidelines
Hemagglutination inhibition
IFN-γ
influenza vaccination
Influenza vaccine
influenza vaccines
interferon-gamma
Neutralizing antibody
Title Relationship between the frequency of influenza vaccination and cell-mediated immunity
URI https://dx.doi.org/10.1016/j.jim.2018.04.008
https://www.ncbi.nlm.nih.gov/pubmed/29684427
https://www.proquest.com/docview/2031030054
https://www.proquest.com/docview/2153632110
Volume 458
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSxxBEC5ESchFjDFxfSwdyEmYONOv6TnKomwS9BTFWzPTDzIis8u6CuvB3251z8yKoHvIcYYqaKqqq7_qrgfAjzI1uaXOJJ57l3ChXFIhME9UllpqqgwxerjQP7-Q40v--1pcr8Gor4UJaZWd7299evTW3Z_jTprH07oONb4U8bQo0Cjjg16oYOd5sPKfTy9pHhjypH3H8EDdv2zGHK-bOhSjZyp2Ow0TJt8-m97DnvEMOtuCzQ48kpN2fZ9hzTXb8KEdJ7nYho_n3UP5F7haJrn9q6ekS8YiCPaIn7XJ0wsy8aRuR5Q8luShNMgZWUjZWBIu9JNYVoKQlNSximS-2IHLs9O_o3HSjVBIDBd0ngjJqoq63EhKlUOFZdYXInSnLqxwvPA5kw4jHusrlltvQ3MppwxzucTNLSz7CuvNpHG7QGzJrVK-kIXJuDVcMZMaQQ1GuYpJwQaQ9sLTpusvHsZc3Oo-kexGo7x1kLdOuUZ5D-BoyTJtm2usIua9RvQrC9Ho_Fexfe-1p3HnBOmVjZvc3yFRnLGGmHUFDR4IkoUgeQDfWtUvV0oLqTin-d7_LWwfPoWvNvX3ANbns3t3iABnXg2jBQ9h4-TXn_HFM_3_-Mk
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDW16CW3apJv0oUJPBRNbL8vHEBo2TXZPSclN2HoQh-Bd0k1h--s7kuWFQrqHXm0NiBlp9I30zQzAlzo3paXOZJ57l3GhXNYgMM9UkVtqmgIxerjQn87k5Jp_vxE3W3A65MIEWmXy_b1Pj946fTlO2jxetG3I8aWIp0WFizI-6D2D7VCdSoxg--T8YjJbO2SMevKhaHgQGB43I83rrg356IWKBU9Dk8mnj6d_wc94DJ29gt2EH8lJP8XXsOW6PXjed5Rc7cGLaXorfwM_1jy323ZBEh-LIN4j_qHnT6_I3JO271Lyuya_aoOSUYTUnSXhTj-LmSWISkkbE0mWq7dwffbt6nSSpS4KmeGCLjMhWdNQVxpJqXJos8L6SoQC1ZUVjle-ZNJh0GN9w0rrbagv5ZRhrpS4v4Vl-zDq5p17B8TW3CrlK1mZglvDFTO5EdRgoKuYFGwM-aA8bVKJ8dDp4l4PXLI7jfrWQd865xr1PYava5FFX19j02A-WET_tUg0-v9NYp8H62ncPEF7defmjz9xUGyzhrB1wxg8EyQLcfIYDnrTr2dKK6k4p-Xh_03sE-xMrqaX-vJ8dnEEL8Ofngn8HkbLh0f3AfHOsvmY1vMfhtX7eg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+the+frequency+of+influenza+vaccination+and+cell-mediated+immunity&rft.jtitle=Journal+of+immunological+methods&rft.au=Otani%2C+Naruhito&rft.au=Shima%2C+Masayuki&rft.au=Ueda%2C+Takashi&rft.au=Ichiki%2C+Kaoru&rft.date=2018-07-01&rft.eissn=1872-7905&rft.volume=458&rft.spage=58&rft_id=info:doi/10.1016%2Fj.jim.2018.04.008&rft_id=info%3Apmid%2F29684427&rft.externalDocID=29684427
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1759&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1759&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1759&client=summon